6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
Sponsor: Martin-Luther-Universität Halle-Wittenberg
Collaborators: German Breast Group